Stephanie Picon
Payments from drug & device makers
What this record shows
This record is dominated by grants: $89,465 of the $90,237 with a category attached, or 99.1%. Biogen accounts for 99.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2021 at $89,465 and has fallen 99.8% since, to $206 in 2025. Among neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $3470.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$89K
- Genentech USA, Inc.$141
- EMD Serono, Inc.$132
- AstraZeneca$86
- Novartis$84
- Banner Life Sciences, LLC$84
- plus $218 from 6 others
What the payments were for
- Grants$89,46599%
- Food & beverage$7721%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 2 | $89,491 |
| Genentech USA, Inc. | 1 | $141 |
| EMD Serono, Inc. | 1 | $132 |
| AstraZeneca | 4 | $86 |
| Novartis | 3 | $84 |
| Banner Life Sciences, LLC | 3 | $84 |
| Bristol Myers Squibb | 4 | $73 |
| Amgen(2 entities) | 4 | $64 |
| AbbVie | 1 | $28 |
| Cycle Pharmaceuticals Inc | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Neurelis, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$141
How this compares
$90,237 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nortriptyline Hcl | 18 | $350 |
| Gabapentin | 16 | $233 |
Paid to pharmacies, not to this prescriber.
Other neurology in Miami
- Diego Torres-RussottoMiami$652K
- Bruno GalloMiami$313K
- Brad HerskowitzMiami$273K
- Flavia NelsonMiami$264K
- Corneliu LucaMiami$257K
- Kottil RammohanMiami$176K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.